Press release
NAFLD Therapeutic Pipeline Reaches New Heights with 90+ Companies Advancing Over 100 Drug Candidates, Reports DelveInsight
NAFLD Pipeline
With the global prevalence of NAFLD steadily increasing-largely due to rising rates of obesity, diabetes, and metabolic disorders-biopharmaceutical companies are intensifying their research and development initiatives. The report provides an in-depth overview of ongoing clinical advancements, emerging therapeutic approaches, trial activities, mechanisms of action, and strategic collaborations that are shaping the future of NAFLD treatment.
Download a free sample report and explore key insights:
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Comprehensive Overview of the Global NAFLD Pipeline
The NAFLD Pipeline Insight report delivers a detailed clinical and commercial assessment of investigational therapies, covering all stages from early discovery to advanced clinical development. Each candidate is evaluated based on its mechanism of action, clinical progress, regulatory designations, development milestones, and associated strategic activities such as partnerships, mergers, acquisitions, and funding.
According to DelveInsight's analysis, industry leaders and emerging biotech firms are making notable progress in developing differentiated therapies to address the significant unmet medical needs of patients suffering from NAFLD and its more severe form, non-alcoholic steatohepatitis (NASH).
Key Companies Driving Innovation in NAFLD Treatment
Several major pharmaceutical and biotech companies are at the forefront of NAFLD drug development, including:
MediciNova, Eli Lilly and Company, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics, Akero Therapeutics, Pfizer, Boehringer Ingelheim, Neuraly, Merck & Co., Rivus Pharmaceuticals, Hepion Pharmaceuticals, and others.
These organizations are actively investigating therapies targeting diverse biological pathways such as metabolic dysfunction, inflammation, fibrosis, lipid metabolism, and liver cell activity.
Access the full therapeutic assessment with a free sample PDF:
https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Promising Emerging Therapies in the NAFLD Pipeline
A wide range of promising drug candidates across Phase I to Phase III clinical trials are expected to significantly impact the NAFLD treatment landscape in the coming years. Some of the key therapies include:
• MN-001 (MediciNova)
• LY3885125 (Eli Lilly)
• AZD7503 (AstraZeneca)
• Lanifibranor (Inventiva Pharma)
• OA-235i (Oasis Pharmaceuticals)
• Resmetirom (Madrigal Pharmaceuticals)
• BMN 255 (BioMarin Pharmaceutical)
• GSK4532990 (GlaxoSmithKline)
• Saroglitazar Magnesium (Zydus Therapeutics)
• Efruxifermin (Akero Therapeutics)
• PF-06865571 (Pfizer)
• BI 3006337 (Boehringer Ingelheim)
• DD01 (Neuraly)
• Efinopegdutide (Merck)
• HU6 (Rivus Pharmaceuticals)
• Rencofilstat (Hepion Pharmaceuticals)
These therapies span multiple drug classes, including small molecules, peptides, and oligonucleotides, and utilize various administration routes such as oral, intravenous, subcutaneous, and intrathecal delivery. This diversity reflects the industry's effort to develop tailored treatments aligned with disease progression and patient needs.
Key Industry Developments Accelerating NAFLD Research
The report highlights several important advancements from 2024 that are driving innovation in the NAFLD space:
• In December 2024, Galectin Therapeutics released findings from its Phase III NAVIGATE trial evaluating belapectin in patients with MASH cirrhosis and portal hypertension.
• In October 2024, PharmaIN Corporation shared interim results from its Phase I study of PHIN-214, aimed at preventing and treating decompensated cirrhosis.
• Also in October 2024, Madrigal Pharmaceuticals completed enrollment in its pivotal Phase III MAESTRO-NASH OUTCOMES trial for resmetirom, with 845 patients participating.
These milestones demonstrate the accelerating pace of clinical innovation and the growing commitment to addressing NAFLD.
NAFLD: A Growing Global Health Concern
Non-Alcoholic Fatty Liver Disease is characterized by the accumulation of fat in the liver unrelated to alcohol consumption. The disease spectrum ranges from simple steatosis to more severe conditions such as NASH, fibrosis, and cirrhosis. As prevalence continues to rise globally, NAFLD has become a major contributor to liver-related complications, including liver failure, hepatocellular carcinoma, and the need for transplantation.
Despite its increasing burden, there are currently no FDA-approved therapies specifically for NAFLD, making the development of effective treatments a critical priority for the healthcare industry.
Learn more about emerging NAFLD therapies by downloading the report:
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Pipeline Segmentation and Analytical Framework
DelveInsight's report categorizes the NAFLD pipeline based on key parameters to provide actionable insights:
Route of Administration:
Includes oral, intravenous, subcutaneous, intrathecal, parenteral, topical, and transdermal approaches.
NAFLD Molecule Type:
• Small molecules
• Peptides
• Oligonucleotides
NAFLD Development Stage:
• Phase III (late-stage)
• Phase II (mid-stage)
• Phase I (early-stage)
• Preclinical and discovery
• Discontinued or inactive programs
This structured analysis helps stakeholders evaluate the maturity, innovation, and potential of pipeline therapies.
NAFLD Market Outlook: Opportunities and Challenges
The NAFLD market is expected to grow rapidly due to several factors, including increasing disease prevalence, rising investments in research and development, and expanding clinical trial activities. Greater awareness of NAFLD as a serious health condition has also encouraged collaborations between pharmaceutical companies and academic institutions.
However, several challenges continue to hinder market growth:
• Absence of effective treatment and prevention strategies
• Dependence on invasive diagnostic methods like liver biopsy
• Complexity and heterogeneity of the disease
• Lack of validated surrogate endpoints in clinical trials
DelveInsight's report provides strategic insights to help stakeholders navigate these challenges and capitalize on emerging opportunities.
Data-Driven Insights Backed by Robust Research
The "Non-Alcoholic Fatty Liver Disease Pipeline Insight, 2026" report is built on extensive research using proprietary databases, clinical trial registries, regulatory filings, company disclosures, and scientific literature. It includes:
• Analysis of partnerships and licensing agreements
• Investment and funding trends
• Target-based therapeutic strategies
• Monotherapy versus combination therapy approaches
• Identification of unmet needs and market gaps
• Expert analyst perspectives and future projections
Explore the complete pipeline analysis and strategic insights:
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=abnewswire&utm_medium=openpr&utm_campaign=apr
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release NAFLD Therapeutic Pipeline Reaches New Heights with 90+ Companies Advancing Over 100 Drug Candidates, Reports DelveInsight here
News-ID: 4431966 • Views: …
More Releases from DelveInsight Business Research
KYNMOBI Sales Outlook 2032: Sublingual Apomorphine Therapy Reshaping Parkinson's …
The evolving treatment landscape for Parkinson's disease is witnessing a significant transformation with the growing adoption of innovative therapies such as KYNMOBI.
According to DelveInsight's latest report, "KYNMOBI Market Size, Forecast, and Market Insight - 2032," the therapy is poised to play a crucial role in addressing unmet needs associated with motor fluctuations in Parkinson's disease patients across the seven major markets (7MM).
The report offers a comprehensive evaluation of KYNMOBI,…
JNJ-1887 Market Forecast 2034: Next-Generation Immunology & Gene Therapy Innovat …
DelveInsight's latest report, "JNJ-1887 Sales Forecast and Market Size Analysis - 2034," highlights the significant commercial potential of JNJ-1887, an emerging next-generation therapy developed by Johnson & Johnson. The investigational therapy is gaining strong attention across the immunology and ophthalmology landscapes, with promising applications in chronic inflammatory disorders and geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).
As healthcare systems worldwide continue to face rising cases of autoimmune diseases…
Prader-Willi Syndrome Market: High-Growth Opportunities for Investors to 2034 - …
DelveInsight's "Prader-Willi Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Prader-Willi Syndrome, historical and forecasted epidemiology as well as the Prader-Willi Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The Prader-Willi Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Prader-Willi Syndrome pipeline…
Spinocerebellar Ataxia Market: Accelerating Growth and Pipeline Impact by 2034- …
DelveInsight's "Spinocerebellar Ataxia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Spinocerebellar Ataxia, historical and forecasted epidemiology as well as the Spinocerebellar Ataxia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Spinocerebellar Ataxia, offering comprehensive insights into the Spinocerebellar Ataxia revenue trends, prevalence, and treatment landscape. The…
More Releases for NAFLD
Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market to Reach 18 …
According to DataM Intelligence, the global Metabolic Dysfunction-Associated Steatohepatitis (MASH) drugs market reached US$ 180.1 million in 2024 and is expected to reach US$ 929.05 million by 2033, growing at a CAGR of 18.1% during 2025-2033, driven by increasing prevalence of metabolic dysfunction-associated steatohepatitis (formerly NASH), growing obesity and diabetes epidemics, strong pipeline advancements in FXR agonists, PPAR agonists, and GLP-1-based therapies, regulatory approvals for first-in-class treatments, and rising healthcare…
Nonalcoholic Fatty Liver Disease (NAFLD) Patient Pool Analysis Market to Reach U …
Pune, India - December 2025 - The global Nonalcoholic Fatty Liver Disease (NAFLD) Patient Pool Analysis Market, valued at USD 1.67 billion in 2024, is projected to reach USD 2.94 billion by 2034, growing at a 5.8% CAGR (2025-2034), according to Exactitude Consultancy. The rapid rise in obesity, type 2 diabetes, metabolic syndrome, and expanded liver health screening are increasing NAFLD patient identification worldwide.
Download Full PDF Sample Copy of Market…
Nonalcoholic Fatty Liver Disease (NAFLD) Patient Pool to Reach 1.7 Billion by 20 …
Nonalcoholic fatty liver disease (NAFLD) has emerged as one of the most pressing global health challenges of the 21st century. Characterized by the accumulation of fat in the liver not caused by alcohol consumption, NAFLD is closely associated with obesity, type 2 diabetes, and metabolic syndrome. In its severe form, nonalcoholic steatohepatitis (NASH), the disease can progress to cirrhosis, liver failure, or hepatocellular carcinoma, making it a major cause of…
Non-Alcoholic Fatty Liver Disease (NAFLD) Market Detailed Industry Report Analys …
Introduction
Non-Alcoholic Fatty Liver Disease (NAFLD) has emerged as one of the most pressing global health challenges of the 21st century. Closely linked to the growing prevalence of obesity, type 2 diabetes, and metabolic syndrome, NAFLD is now the most common liver disorder worldwide. It ranges from simple fat accumulation in the liver (steatosis) to the more severe inflammatory stage known as Non-Alcoholic Steatohepatitis (NASH), which can progress to fibrosis, cirrhosis,…
Non-Alcoholic Fatty Liver Disease (NAFLD) Market to Rise at 5.98% CAGR, Reaching …
BREAKING: The Non-Alcoholic Fatty Liver Disease NAFLD market is positioned to become the #1 game-changing force in the global Healthcare sector by 2035, creating unprecedented growth opportunities for manufacturers, technology providers, enterprise clients, solution developers and strategic investors worldwide.
This exclusive deep-dive report delivers comprehensive analysis of the rapidly evolving Non-Alcoholic Fatty Liver Disease NAFLD industry, uncovering breakthrough technological advancements, critical market milestones and transformative future projections. It explores the revolutionary…
Non Alcoholic Fatty Liver Disease (NAFLD) Market to Witness Growth by 2032, Esti …
DelveInsight's "Non Alcoholic Fatty Liver Disease (NAFLD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Non Alcoholic Fatty Liver Disease (NAFLD), historical and forecasted epidemiology as well as the Non Alcoholic Fatty Liver Disease (NAFLD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Non Alcoholic Fatty Liver Disease (NAFLD) market report provides current treatment practices, emerging drugs,…
